PRESS RELEASE: Patients Rising Releases New Rare Disease Drug Assessment Standards Aimed at Improving Health Equity
Press Contact: Sarah Shelsonsshelson@riesterpublicaffairs.com New framework for the evaluation of rare disease therapies prioritizes patient experiences, feedback, and needs WASHINGTON — Patients Rising, a non-profit organization that advocates on behalf of patients...
Healthcare That is Fit for Service
Veterans Have An Urgent Need for Better HealthcareVeterans are American heroes that deserve the highest level of respect, care and dignity that our nation can offer. Yet, Uncle Sam has fallen short on the promise to have the backs of the men and women who wore the...
ICER’s Latest: A draft evidence report on treatments for vasomotor symptoms of menopause
On October 11, 2022 2021, ICER released a draft evidence report, “Fezolinetant for Moderate to Severe Vasomotor Symptoms Associated with Menopause.” This is the first step in ICER’s assessment process that is current scheduled to conclude with the release of a final...
Op-Ed: Medicare’s cuts to home health are a step in the wrong direction
By Terry Wilcox
Co-Founder and CEO, Patients Rising
ICER’s Latest: A draft evidence report on gene therapies for Hemophilia A and B
On September 13, 2022 2021, ICER released a new draft evidence report, “Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in December...
ICER’s Latest: A draft evidence report on medications for obesity management
On July 13, 2022 2021, ICER released its draft evidence report, “Medications for Obesity Management.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in October 2022. ICER’s report reviews four medicines...
ICER’s Latest: Draft Evidence Report on New ALS Treatments
On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This is the first step in ICER's review process. A final evidence report is expected to be released in mid-September. Background on ALS...
FTC Investigating Pharmacy Benefit Managers for Practices Impacting Patient Access
Earlier this month, the Federal Trade Commission (FTC) announced that it had launched a new inquiry into business practices of pharmacy benefit managers (PBMs). Specifically, the the five-member commission said that it would "scrutinize the impact of vertically...
New Study: FDA consistently approves cancer treatments faster than its counterparts in Europe
Over the past decade, the Food and Drug Administration (FDA) has significantly outpaced the European Medicines Agency (EMA) in approving new cancer treatments. This is according to a recent study published in JAMA Network Open. The study included a cross-sectional...
Recommended Reading: Why So Slow? Legislators Take on Insurers’ Delays in Approving Prescribed Treatments
Andrew Bade, who was diagnosed with Type 1 diabetes nearly two decades ago, is accustomed to all the medical gear he needs to keep his blood sugar under control. His insulin pump contains a disposable insulin cartridge, and a plastic tubing system with an adhesive...